Bipolar disorder: candidate drug targets
- 1 June 2008
- journal article
- review article
- Published by Wiley in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Vol. 75 (3) , 226-247
Abstract
Current pharmacotherapy for bipolar disorder is generally unsatisfactory for a large number of patients. Even with adequate modern bipolar pharmacological therapies, many afflicted individuals continue to have persistent mood episode relapses, residual symptoms, functional impairment, and psychosocial disability. Creating novel therapeutics for bipolar disorder is urgently needed. Promising drug targets and compounds for bipolar disorder worthy of further study include both systems and intracellular pathways and targets. Specifically, the purinergic system, the dynorphin opioid neuropeptide system, the cholinergic system (muscarinic and nicotinic systems), the melatonin and serotonin [5‐hydroxytryptamine receptor 2C] system, the glutamatergic system, and the hypothalamic‐pituitary adrenal axis have all been implicated. Intracellular pathways and targets worthy of further study include glycogen synthase kinase‐3 protein, protein kinase C, and the arachidonic acid cascade. Mt Sinai J Med 75:225–246, 2008. © 2008 Mount Sinai School of MedicineKeywords
This publication has 220 references indexed in Scilit:
- No evidence for association between 19 cholinergic genes and bipolar disorderAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007
- Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2007
- Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J miceNeuropharmacology, 2007
- Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive SymptomsBiological Psychiatry, 2007
- Antidepressant Efficacy of the Antimuscarinic Drug ScopolamineArchives of General Psychiatry, 2006
- Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039Biochemical and Biophysical Research Communications, 2004
- Neuronal nicotinic receptor inhibition for treating mood disorders preliminary controlled evidence with mecamylamineDepression and Anxiety, 2002
- Purinergic dysfunction in mania: an integrative modelMedical Hypotheses, 2002
- Ketoconazole in bipolar patients with depressive symptoms: a case series and literature reviewBipolar Disorders, 2001
- Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorderBipolar Disorders, 1999